PRAX Relative Valuation
PRAX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PRAX is overvalued; if below, it's undervalued.
Historical Valuation
Praxis Precision Medicines Inc (PRAX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 1577.94 is considered Overvalued compared with the five-year average of -4.80. The fair price of Praxis Precision Medicines Inc (PRAX) is between 23.43 to 40.28 according to relative valuation methord. Compared to the current price of 53.63 USD , Praxis Precision Medicines Inc is Overvalued By 33.13%.
Relative Value
Fair Zone
23.43-40.28
Current Price：53.63
33.13%
Overvalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
2.40
P/B
Median3y
2.23
Median5y
2.41
-15.01
FCF Yield
Median3y
-85.78
Median5y
-62.00
Competitors Valuation Multiple
The average P/S ratio for PRAX's competitors is 478.94, providing a benchmark for relative valuation. Praxis Precision Medicines Inc Corp (PRAX) exhibits a P/S ratio of 1577.94, which is 229.46% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Praxis Precision Medicines Inc (PRAX) currently overvalued or undervalued?
What is Praxis Precision Medicines Inc (PRAX) fair value?
How does PRAX's valuation metrics compare to the industry average?
What is the current P/B ratio for Praxis Precision Medicines Inc (PRAX) as of Jul 17 2025?
What is the current FCF Yield for Praxis Precision Medicines Inc (PRAX) as of Jul 17 2025?
What is the current Forward P/E ratio for Praxis Precision Medicines Inc (PRAX) as of Jul 17 2025?